100 related articles for article (PubMed ID: 32584701)
1. Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression.
Piercey OA; Loh Z; Chan J; Chong G; Grigg A; Cheema S; Gill G; Whybird M; Cushion T; Hawkes EA
JCO Oncol Pract; 2020 Nov; 16(11):e1315-e1323. PubMed ID: 32584701
[TBL] [Abstract][Full Text] [Related]
2. Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission.
Hawkes EA; Loh Z; Estacio O; Chong G; Ha FJ; Gilbertson M; Grigg A
Br J Cancer; 2018 Aug; 119(5):546-550. PubMed ID: 30033446
[TBL] [Abstract][Full Text] [Related]
3. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
[TBL] [Abstract][Full Text] [Related]
4. Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.
El-Galaly TC; Mylam KJ; Bøgsted M; Brown P; Rossing M; Gang AO; Haglund A; Arboe B; Clausen MR; Jensen P; Pedersen M; Bukh A; Jensen BA; Poulsen CB; d'Amore F; Hutchings M
Am J Hematol; 2014 Jun; 89(6):575-80. PubMed ID: 24493389
[TBL] [Abstract][Full Text] [Related]
5. Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study.
Lynch RC; Sundaram V; Desai M; Henry S; Wood D; Daadi S; Hoppe RT; Advani R
JCO Oncol Pract; 2020 Sep; 16(9):e902-e911. PubMed ID: 32369413
[TBL] [Abstract][Full Text] [Related]
6. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
9. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R
Izutsu K; Minami Y; Fukuhara N; Terui Y; Jo T; Yamamoto G; Ishikawa T; Kobayashi T; Kiguchi T; Nagai H; Ohtsu T; Kalambakas S; Fustier P; Midorikawa S; Tobinai K
Int J Hematol; 2020 Mar; 111(3):409-416. PubMed ID: 31858429
[TBL] [Abstract][Full Text] [Related]
11. Treatment of indolent lymphoma in Germany - results of a representative population-based survey.
Schmidt C; Fetscher S; Görg C; Kornek P; Nusch A; Kegel T; Kellermann L; Hiddemann W; Fingerle-Rowson G; Dreyling M
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):204-11. PubMed ID: 21575925
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
15. Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma.
Kang KW; Lee SR; Kim DS; Yu ES; Sung HJ; Kim SJ; Choi CW; Park Y; Kim BS
PLoS One; 2018; 13(2):e0192656. PubMed ID: 29444176
[TBL] [Abstract][Full Text] [Related]
16. Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies.
Elis A; Blickstein D; Klein O; Eliav-Ronen R; Manor Y; Lishner M
Am J Hematol; 2002 Jan; 69(1):41-4. PubMed ID: 11835330
[TBL] [Abstract][Full Text] [Related]
17. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma-A case report.
Belančić A; Vranić L; Ševeljević I; Hadžisejdić I; Načinović AD; Jonjić N
Pathol Res Pract; 2019 Jan; 215(1):222-228. PubMed ID: 30385086
[TBL] [Abstract][Full Text] [Related]
19. Optimal disease surveillance strategies in non-Hodgkin lymphoma.
Cohen JB; Flowers CR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):481-7. PubMed ID: 25696898
[TBL] [Abstract][Full Text] [Related]
20. Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy.
Cheah CY; Dickinson M; Hofman MS; George A; Ritchie DS; Prince HM; Westerman D; Harrison SJ; Burbury K; Wolf M; Januszewicz H; Herbert KE; Carney DA; Tam C; Seymour JF
Ann Hematol; 2014 Jul; 93(7):1193-200. PubMed ID: 24595733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
